4Moving Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

4Moving Biotech is a French biotech founded in 2017, focused on developing first-in-class disease-modifying osteoarthritis drugs (DMOADs). Its lead program, 4P004, a GLP-1 analog, has completed Phase 1 and entered a Phase 2a proof-of-concept study, supported by a €12 million financing round in early 2026. The company employs a distinctive strategy integrating AI-driven in-silico trials and analysis of large-scale patient data to de-risk and accelerate clinical development in the vast, underserved osteoarthritis market.

OsteoarthritisMusculoskeletal

Technology Platform

AI-driven clinical development platform utilizing in-silico trials and real-world data analysis from millions of patients to optimize trial design and patient selection.

Opportunities

The global osteoarthritis market represents a massive, underserved opportunity with over 595 million patients and an estimated annual sales potential of €3-4 billion for a disease-modifying therapy.

The proven commercial success of GLP-1 analogs in other indications provides a strong precedent for market adoption and reimbursement.

Risk Factors

The company faces high clinical risk as its future depends entirely on the unproven success of its single asset, 4P004, in ongoing trials.

It also operates in a competitive DMOAD development landscape where larger competitors could reach the market first.

Competitive Landscape

The DMOAD space is highly competitive but lacks an approved product, with numerous biopharma companies investigating diverse mechanisms. 4Moving's key differentiation is its novel application of GLP-1 analogs for OA and its AI-driven development strategy, but it must outpace competitors in clinical development to secure a first-mover advantage.

More companies in Small Molecule Drugs →More companies in France →